Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Mar 16, 2015 11:57am

98 Views

Post# 23525516

RE:RE:Rough RRR Comparison for Mace: No Spin Zone

Hi GV: I appreciate your post and question.

I think (but am not 100% sure) that the .95 you talk about is the actual rate of MACE. Not the reduction in risk of MACE. Thus, it would not be correct to say that the RRR reduction is 95%....

Just my interpretation.

Bullboard Posts

Southern Ontario mineral processing operation receives green fund support